Revance Therapeutics (NASDAQ: RVNC) reported Q1 EPS of ($0.94), $0.03 worse than the analyst estimate of ($0.91). Revenue for the quarter came in at $25.3 million versus the consensus estimate of $24.01 million.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.